This site is intended for health professionals only!

Dabigatran compares well against enoxaparin

teaser

The investigational oral anticoagulant dabigatran etexilate is noninferior to enoxaparin in preventing venous thromboembolism (VTE) and all-cause mortality after total hip replacement surgery, when given for an extended average period of 33 days, a study has found.

Phase III data on the dabigatran were presented at the 21st Congress of the International Society on Thrombosis and Haemostasis, held in Geneva on 7-13 July.

The drug is a direct thrombin inhibitor that specifically and reversibly inhibits thrombin, the key enzyme involved in clotting. It is administered as a once-daily dose and does not require titration or coagulation monitoring.

The RE-NOVATE trial involved more than 3,000 patients who had undergone total hip replacement surgery, randomised to once-daily dabigatran etexilate (220mg or 150mg) or enoxaparin 40mg. Treatment was administered for an average of 33 days.

Incidences for the primary efficacy composite endpoint of total VTE and all-cause mortality were 6.0% for dabigatran 220mg, 8.6% for dabigatran 150mg and 6.7% for enoxaparin 40mg. This endpoint was within the pre-specified noninferiority margin of 7.7% in both dabigatran dose groups.

Safety was evaluated for 3,463 patients receiving study treatment: the incidences of major bleeding events were similar in all treatment groups, 2.0%, 1.3% and 1.6% for dabigatran 220mg and 150mg and enoxaparin 40mg, respectively. The incidence of liver enzyme elevations and acute coronary events during the treatment or during the follow-up period did not differ significantly between the treatment groups.

National Electronic Library for Medicines 12/7/2007

 

 

 



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine